Intra-Cellular Therapies, Inc. with ticker code (ITCI) now have 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 100 and 59 calculating the average target price we see $77.83. Given that the stocks previous close was at $49.17 and the analysts are correct then we can expect a percentage increase in value of 58.3%. Also worth taking note is the 50 day moving average now sits at $54.16 while the 200 day moving average is $56.03. The total market capitalization for the company now stands at 4.65B. The stock price is currently at: 48.4 USD
The potential market cap would be $7,361,691,359 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 3.85 and a -16.27% return on assets.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
